508 related articles for article (PubMed ID: 29442211)
21. Circulating tumor cells are a good predictor of tumor recurrence in clinical patients with gastric cancer.
Li W; Zhang X; Yang Y; Lin J; Zhou K; Sun R; Dang C; Diao D
Sci Rep; 2024 Jun; 14(1):12758. PubMed ID: 38830909
[TBL] [Abstract][Full Text] [Related]
22. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer.
Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M
Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830
[TBL] [Abstract][Full Text] [Related]
23. Correlation of circulating angiogenic factors with circulating tumor cells and disease recurrence in patients undergoing curative resection for colorectal liver metastases.
Rahbari NN; Reissfelder C; Mühlbayer M; Weidmann K; Kahlert C; Büchler MW; Weitz J; Koch M
Ann Surg Oncol; 2011 Aug; 18(8):2182-91. PubMed ID: 21598056
[TBL] [Abstract][Full Text] [Related]
24. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability.
Shi HJ; Jin C; Fu DL
World J Gastroenterol; 2016 Dec; 22(45):10024-10037. PubMed ID: 28018110
[TBL] [Abstract][Full Text] [Related]
25. Serum SPan-1 Is a Significant Risk Factor for Early Recurrence of Pancreatic Cancer after Curative Resection.
Hosokawa Y; Nagakawa Y; Sahara Y; Takishita C; Katsumata K; Tsuchida A
Dig Surg; 2017; 34(2):125-132. PubMed ID: 27658221
[TBL] [Abstract][Full Text] [Related]
26. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
Kim NH; Kim HJ
Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
[TBL] [Abstract][Full Text] [Related]
27. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
[TBL] [Abstract][Full Text] [Related]
28. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.
Thomas RM; Truty MJ; Kim M; Kang Y; Zhang R; Chatterjee D; Katz MH; Fleming JB
Ann Surg Oncol; 2015; 22(6):1884-92. PubMed ID: 25404477
[TBL] [Abstract][Full Text] [Related]
29. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma.
Poruk KE; Valero V; Saunders T; Blackford AL; Griffin JF; Poling J; Hruban RH; Anders RA; Herman J; Zheng L; Rasheed ZA; Laheru DA; Ahuja N; Weiss MJ; Cameron JL; Goggins M; Iacobuzio-Donahue CA; Wood LD; Wolfgang CL
Ann Surg; 2016 Dec; 264(6):1073-1081. PubMed ID: 26756760
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
[TBL] [Abstract][Full Text] [Related]
32. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer.
Bissolati M; Sandri MT; Burtulo G; Zorzino L; Balzano G; Braga M
Tumour Biol; 2015 Feb; 36(2):991-6. PubMed ID: 25318603
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of B2M and loss of ALK7 expression are associated with invasion, metastasis, and poor-prognosis of the pancreatic ductal adenocarcinoma.
Liu C; Yang Z; Li D; Liu Z; Miao X; Yang L; Zou Q; Yuan Y
Cancer Biomark; 2015; 15(6):735-43. PubMed ID: 26406402
[TBL] [Abstract][Full Text] [Related]
34. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study.
Aziz MH; Sideras K; Aziz NA; Mauff K; Haen R; Roos D; Saida L; Suker M; van der Harst E; Mieog JS; Bonsing BA; Klaver Y; Koerkamp BG; van Eijck CH
Ann Surg; 2019 Jul; 270(1):139-146. PubMed ID: 29334554
[TBL] [Abstract][Full Text] [Related]
35. Circulating Tumor Cells are an Independent Predictor of Shorter Survival in Patients Undergoing Resection for Pancreatic and Periampullary Adenocarcinoma.
Hugenschmidt H; Labori KJ; Brunborg C; Verbeke CS; Seeberg LT; Schirmer CB; Renolen A; Borgen EF; Naume B; Wiedswang G
Ann Surg; 2020 Mar; 271(3):549-558. PubMed ID: 30216219
[TBL] [Abstract][Full Text] [Related]
36. Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer.
Meyer CP; Pantel K; Tennstedt P; Stroelin P; Schlomm T; Heinzer H; Riethdorf S; Steuber T
Urol Oncol; 2016 May; 34(5):235.e11-6. PubMed ID: 26795608
[TBL] [Abstract][Full Text] [Related]
37. Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma.
Sergeant G; Roskams T; van Pelt J; Houtmeyers F; Aerts R; Topal B
BMC Cancer; 2011 Jan; 11():47. PubMed ID: 21281486
[TBL] [Abstract][Full Text] [Related]
38. Dynamic changes of different phenotypic and genetic circulating tumor cells as a biomarker for evaluating the prognosis of RCC.
Wang ZL; Zhang P; Li HC; Yang XJ; Zhang YP; Li ZL; Xue L; Xue YQ; Li HL; Chen Q; Chong T
Cancer Biol Ther; 2019; 20(4):505-512. PubMed ID: 30359544
[TBL] [Abstract][Full Text] [Related]
39. Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma.
Schulze K; Gasch C; Staufer K; Nashan B; Lohse AW; Pantel K; Riethdorf S; Wege H
Int J Cancer; 2013 Nov; 133(9):2165-71. PubMed ID: 23616258
[TBL] [Abstract][Full Text] [Related]
40. Improved Risk Stratification by Circulating Tumor Cell Counts in Pancreatic Cancer.
Effenberger KE; Schroeder C; Hanssen A; Wolter S; Eulenburg C; Tachezy M; Gebauer F; Izbicki JR; Pantel K; Bockhorn M
Clin Cancer Res; 2018 Jun; 24(12):2844-2850. PubMed ID: 29559560
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
